SCHEDULE 13G: FMR LLC and Abigail P. Johnson Disclose 9.0% Stake in Veracyte Inc.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly disclosed a beneficial ownership of 9.0% of Veracyte Inc.'s common stock as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 7,020,450.60 shares of Veracyte Inc. common stock.
• This ownership represents 9.0% of the total outstanding common stock of Veracyte Inc.
• FMR LLC holds sole voting power over 7,014,798.00 shares.
• Both FMR LLC and Abigail P. Johnson hold sole dispositive power over 7,020,450.60 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Veracyte Inc.
• Fidelity Management & Research Company LLC, a subsidiary of FMR LLC, is identified as an entity that beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is a routine disclosure, the maintenance of a significant stake by a prominent institutional investor like FMR LLC can be viewed favorably by the market, suggesting continued confidence in the company.

Positives

• The disclosure of a significant 9.0% stake by a major institutional investor like FMR LLC and its leadership can be interpreted as a vote of confidence in Veracyte Inc.'s long-term prospects.
• The passive nature of the investment, as certified in the filing, suggests a stable, long-term holding rather than an activist position.

Risks

• While the filing states the shares are not held for control, a large institutional stake could still exert influence on corporate decisions over time, even if passive.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Veracyte Inc.'s future performance or strategic outlook.

Industry Context

This filing is a routine disclosure of significant beneficial ownership by a large asset management firm in a publicly traded company within the healthcare/biotechnology sector. Such disclosures are common and provide transparency into institutional holdings, which can influence market perception of a company's stability and investment appeal.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially influencing investor confidence and perception of the stock's stability.
• Company Management: Awareness of a large, passive institutional holder may influence long-term strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Veracyte Inc., FMR LLC, Abigail P. Johnson, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Healthcare, Biotechnology